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December 20121824 Abstractsconfidence interval, 0.203-0.802; P  .01). Treatment with anakinra start-
ing 3 or 7 days after elastase exposure significantly reduced aortic dilation
compared with vehicle alone. Treatment starting 3 days after elastase re-
sulted in 43.7% 8.3% dilation vs 86.4% 3.5% dilation with vehicle alone
(P  .0005). Anakinra treatment starting 7 days after elastase exposure
reduced aortic dilation from 82.4%  6.9% with vehicle alone to 52.9% 
1.4% (P  .005). Aortas treated with anakinra demonstrated less macro-
phage and neutrophil infiltration, less elastin degradation, and less IL-1.
Conclusions: IL-1 signaling was critical for AAA formation, and
inhibition of its corresponding receptor through receptor antagonism with
anakinra attenuated AAA formation, macrophage and neutrophil infiltra-
tion, and elastin degradation. Furthermore, delayed initiation of IL-1R
antagonism after early aneurysm formation inhibited AAA progression,
suggesting that IL-1 pathway antagonism may function as a novel treat-
ment strategy for AAAs.
A Novel Depletion Approach Attenuates a Surge of CD34 Progenitors
After Vascular Injury: Implications for Restenotic Vascular Disease
Bryan Tillman, Justine Kim, Adriana Harbuzariu. University of Pittsburgh
School of Medicine, Pittsburgh, Pa
Introduction: Intimal hyperplasia is an overactive healing response
that leads to failure of half of all vascular interventions in 5 years. Increas-
ing evidence suggests that circulating progenitor cells expressing the marker
CD34 play an important role in this disease. Several studies have highlighted
either a direct cellular contribution to intimal lesions or by fostering a
favorable environment for restenosis. Despite their evolving importance in
this clinically important disease, the kinetics of CD34 cell mobilization after
vascular injury are not known. In addition, there is no way to specifically
intervene on these cells. In this study, we investigated the timecourse of
CD34-positive progenitor cells after vascular injury and examined whether
an affinity pheresis approach could mediate systemic depletion of CD34-
positive cells at the time of vascular injury in a large-animal model.
Methods: An ovine model underwent placement of an arteriovenous
polytetrafluorethylene graft between the carotid and jugular veins. The
contralateral carotid underwent balloon angioplasty. Endothelial injury in
this model was confirmed by scanning electron microscopy. The first groups
of animals underwent flow cytometric assessment of CD34/vascular endo-
thelial factor receptor 2-positive cells after vascular (n  3) and a control,
nonvascular surgery (n  3). Next, separate groups underwent vascular
injury, and over 14 days, the model underwent serial depletion using affinity
pheresis toward the progenitor cell marker CD34 (n 3) or a mock control
(n  4). Cells bound to the affinity system were eluted enzymatically and
examined by flow cytometry. Finally, complete blood counts were compared
between the study groups for changes after affinity pheresis.
Results: Our findings suggest a surge of CD34-positive cells after
vascular intervention that is not observed after control surgical procedures
(Fig 1). Our pheresis group revealed that the surge can be attenuated by a
CD34 affinity pheresis but not by a mock control (Fig 2). Consistent with
these findings, cells recovered from the affinity cartridge revealed large
numbers of CD34-positive cells that were not found in the control group.
Finally, our findings revealed that even after multiple sessions with an affinity
pheresis device, complete blood counts remain essentially unchanged.Fig.Conclusions: This study is the first to document a surge of CD34-
ositive progenitors that appears to be limited to macrovascular injury. This
nding may have important implications on the pathology of vascular
estenosis. We further conclude that CD34 affinity pheresis can mediate
ignificant in vivo depletion of circulating progenitor cells. Our results also
ndicate that the specificity of this depletion has minimal impact on clinical
easures of blood composition. Given the evolving role of these cells in the
athology of restenosis, this approach may have important clinical implica-
ions. Future studies will evaluate the implications of this depletion on
ecurrent vascular disease.
-2a Agonist Dexmedetomidine Interrupts Macrophage Toll-Like
eceptor 4 Signaling in Murine Model of Spinal Cord
schemia–Reperfusion
arshall T. Bell, Viktor A. Agoston, Ferenc Puskas, Joseph C. Cleveland, Jr,
avid A. Fullerton, Kristen Freeman, Fabia Gamboni, Paco Herson, Joshua
ares, Michael J. Weyant, T. Brett Reece. University of Colorado, Aurora,
olo
Introduction: Paraplegia persists after thoracoabdominal aortic inter-
entions despite investigation into preventative pharmacologic adjuncts.
he 
-2a adrenergic receptor agonist, dexmedetomidine, has been shown to
reserve neurologic function and neuronal viability in a murine model of
pinal cord ischemia–reperfusion, although the mechanism remains elusive.
e hypothesize that dexmedetomidine will blunt the inflammation of
eperfusion effects in vivo after thoracic aortic occlusion with in vitro
emonstration of microglial inhibition via blunted Toll-like receptor (TLR)
signaling
Methods: Adult male C57BL/6 mice underwent 4 minutes of aortic
cclusion. Treatment groups received 25 g/kg dexmedetomidine at rep-
rfusion and at 12-hour intervals postprocedurally. Functional scoring was
one at 6 hours after surgery and at 12-hour intervals until 60 hours, when
pinal cords were removed and examined for neuronal viability and cytokine
roduction. Spinal cords from identical mice were removed for microglial
solation culture. Cells were grown to confluence and stimulated with the
LR-4 agonist LPS 10 ng/mL in presence of dexmedetomidine or vehicle
ontrol. Media was then removed for cytokine analysis. All treatment groups
ere compared with ischemic controls and significance determined by P 
05.
Results: Dexmedetomidine treatment significantly preserved neuro-
ogic function, cytoarchitecture, and neuronal viability in the murine spinal
ord. Treatment was associated with significantly reduced IL-6 production
t 6 and 60 hours. Microglial cells stimulated with LPS had production of
roinflammatory cytokines tumor necrosis factor-
 and interleukin-6, which
as significantly attenuated with treatment of dexmedetomidine.
Conclusions: The 
-2a agonist, dexmedetomidine, preserved neu-
ologic function and attenuated proinflammatory cytokine production in
n vivo and in vitro murine models. Furthermore, this relationship
ppears to occur through interruption of TLR-4–mediated microglial
ctivation and cytokine production. This involvement of TLR-4 signal-
ng in dexmedetomidine protection provides an insight into the mecha-
ism of paralysis after thoracic aortic interventions to guide future
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Volume 56, Number 6 Abstracts 1825Homocysteine Upregulates Expression of NR2D-containing N-methyl-
D-aspartate Receptors in a Rat Carotid Endarterectomy Model
Mohammed Moursi, Hongju Deng, John Nyalala. University of Arkansas
for Medical Sciences, Little Rock, Ark
Introduction: We previously demonstrated that N-methyl-D-aspartate
(NMDA) receptor exists in vascular smooth muscle and endothelial cells
and that homocysteine may act via the NMDA receptor to increase
neointimal hyperplasia. In the current study, we first investigated the
expression profile of the constituent NMDA receptor subunits after a
vascular surgical procedure in an environment of hyperhomocysteinemia
in a rat model; and second, we evaluated the expression of NR2D-
containing NMDA receptor at transcriptional and protein level after
vascular injury in a rat model.
Methods: Rats were fed a homocysteine-supplemented diet or a con-
trol diet for 2 weeks before carotid endarterectomy (CEA) and continued on
preoperative diets. Animals were euthanized at 3, 8, or 14 days postopera-
tively and carotid arteries were processed for molecular studies (quantitative
real-time reverse transcriptase polymerase chain reaction, Western blot) and
histomorphometry.
Results: All five known NMDA receptor subunits (NR1, NR2A-2D)
messenger (m)RNAs were expressed in carotid arteries of homocysteinemic
rats at 2 weeks after CEA, but at different levels. Receptor subunit NR2D
mRNA rose sixfold vs NR2A, fourfold vs NR2B or NR1, and three times vs
NR2C (P .05). Protein bands corresponding to NR1 and NR2A-2D also
showed immunoreactivity at 2 weeks after injury. The receptor subunit
NR2D protein band was prominently expressed in the carotid artery com-
pared with other subunits. This robust NR2D receptor subunit protein
expression in the postinjury carotid artery is mimicking the high level of
mRNA expression observed using polymerase chain reaction. Homocysteine
supplementation for 8 or 14 days, but not 3 days after CEA, triggered
significant upregulation of both NR2D mRNA and protein vs control CEA
(all P  .0004). Furthermore, rats fed the control diet for 8 or 14 days, but
not 3 days after CEA, revealed a remarkable increase in NR2D mRNA and
protein expressions vs control non-CEA (intact) arteries (all P  .019).
Although damage to the carotid artery appears to upregulate the expression
of the NR2D receptor subunit, there was a quantitative difference in
response to vascular injury alone vs injury supplemented with homocysteine
at 3, 8, or 14 days postoperatively, with the latter being higher. Neointimal
hyperplasia, expressed as percentage luminal stenosis of the carotid artery
was significantly increased in CEA plus homocysteine vs CEA on control
diets at 2 weeks (P  .0001).
Conclusions: This preliminary study is the first to show that mRNA
and protein for NR2D-containing NMDA receptor were upregulated in the
carotid artery at 8 or 14 days after CEA in a time-dependent manner, with or
without homocysteine supplementation. CEA with homocysteine supple-
mentation for 2 weeks triggered a significant increase in luminal stenosis.
This morphologic and biochemical evidence represents the basis for our
assumption that the NR2D receptor subunit may be involved in homo-
cysteine-mediated hyperplastic response. We suggest that the NR2D
Fig 2.receptor subunit may constitute a useful therapeutic target to prevent/
attenuate neointimal proliferation after vascular injury.
r
mtherectomy Offers no Benefits Over Balloon Angioplasty in Tibial
nterventions for Critical Limb Ischemia
evin E. Todd, Jr, Christian A. Maurer, Johnathan A. Higgins, Jung H.
im, Sadaf S. Ahanchi, JeanM. Panneton. Eastern VirginiaMedical School,
orfolk, Va
Introduction: Endovascular adjuncts, like atherectomy, have been
eveloped in order to improve outcomes for patients undergoing endovas-
ular treatment for peripheral arterial disease (PAD). The true impact of
therectomy on endovascular outcomes remains to be determined, and no
ata exist on the influence of atherectomy on tibial interventions. Our study
ompares the early and late outcomes of tibial intervention with angioplasty
s atherectomy.
Methods: We completed a retrospective review of all tibial interven-
ions between 2008 and 2010. Preprocedural, procedural, and postproce-
ural data were collected using paper and electronic systems. Factors affect-
ng patient outcomes were analyzed using single and multivariate analysis,
ox regression analysis, and Kaplan-Meier life-table curves. Primary out-
omes were primary, primary assisted, and secondary patency rates, as well as
imb salvage and survival.
Results: After review, 480 tibial interventions were completed for 421
imbs, 418 (87%) presented with critical limb ischemia (CLI) and 62 (13%)
ith claudication. A total of 192 isolated tibial interventions were com-
leted, and 288 multisegment interventions were completed. The CLI
ohort of 418 limbs was selected for analysis. These patients were a mean age
f 71 years, with a mean follow-up time of 16  15 months (range, 0-59
onths). Moat patients (60%) were men, with predominant risk factors of
ypertension (92%), tobacco use (64%), diabetes (72%), hyperlipidemia
65%), and chronic kidney disease (39%). Of the 418 limbs, 339 underwent
ercutaneous transluminal angioplasty (PTA): 333 PTA alone and six
TAstent. The remaining 79 limbs received atherectomy (33 laser, 13
irectional, 33 orbital) alone or in conjunction with PTA (11 atherectomy
nly, 68 atherectomyPTA). The groups did not differ significantly in age,
ex, risk factors, occlusion vs stenosis, or technical success. The atherectomy
roup had significantly more TransAtlantic Inter-Society Consensus
TASC) B lesions (54% vs 38%, P  .013), and the PTA group had
ignificantly more TASC D lesions (25% vs 13%, P  .049). TASC A and C
esions did not differ significantly between the two groups. No significant
ifferences existed with respect to the early (30-day) outcomes of loss of
atency (11% vs 13%, P .70), complications (9% vs 13%, P .41), or major
mputation (17% vs 13%, P  .34). Furthermore, there was no difference
etween treatment groups in symptomatic relief at first follow-up (61% vs
5%, P  .53) or Rutherford score improvement (70% vs 69%, P  .81).
aplan-Meier analysis revealed no difference in primary outcomes of PTA vs
therectomy at the 12-month and 36-month assessments: primary patency
69% and 55% vs 61% and 46%, P .15), primary assisted patency (83% and
1% vs 85% and 67%, P .80), secondary patency (94% and 89% vs 95% and
9%, P  .89), limb salvage (79% and 70% vs 81% and 77%, P  .49), or
urvival (77% and 56% vs 80% and 50%).
Conclusions: The adjunctive use of atherectomy offered no improve-
ent over PTA in early or late outcomes in patients with CLI who under-
ent endovascular tibial interventions. Considering the additional cost and
ncreased procedural time, these findings put into question the routine use of
djunctive atherectomy.
rospective, Multicenter Analysis of Perioperative Patency for Tibial
ypass: Comparison Among Different Conduit Configurations
ao-Ngoc H. Nguyen, Richard F. Neville, Richard Amdur, Mustafa Abugi-
eiri, Anton Sidawy. George Washington University, Washington, DC
Introduction: Despite advances in endovascular techniques, tibial
ypass may still be required for revascularization to obtain healing and limb
alvage. Perioperative (30-day) graft patency is an important outcome
arameter reflecting technical considerations and acute graft thrombosis.
oth are important prerequisites for long-term patency. In this analysis, the
0-day patency of the great saphenous vein (GSV) is compared with alter-
ative conduit configurations for tibial bypasses.
Methods: The study cohort consisted of all primary tibial bypasses
ntered in a prospective, multicenter database (American College of Sur-
eons-National Surgical Quality Improvement Program) from 2006 to
010 with exclusion of reoperative cases. The bypasses were divided into six
roups: (1) GSV, (2) prosthetic conduit, (3) prosthetic conduit with a distal
nastomotic venous adjunct, such as a cuff or patch, (4) composite graft of
xpanded polytetrafluoroethylene and a vein segment, (5) spliced autoge-
ous vein, and (6) arm vein. Thirty-day graft failure, patient demographics,
nd operative details were compared among groups. Univariate associations
etween patient factors and conduit were tested, and those variables that had
 .20 were used in a multivariate model to predict patency.
Results:A total of 5375 tibial bypasses were analyzed by conduit: GSV,
983 (74%); prosthetic, 889 (17%); spliced vein, 160 (3%); prosthetic with
djunct, 112 (2%); arm vein, 93 (2%); and composite, 91 (2%). There was no
ifference among groups in terms of diabetes, renal failure, tobacco use, or
est pain as an indication for bypass. There was no difference in perioperative
ortality based on conduit. After adjusting for gender, age, weight, race,
